New Orleans, LA – Research led by T. Cooper Woods, PhD, Assistant Professor of Pharmacology and Experimental Therapeutics at LSU Health Sciences Center New Orleans, and Director of the Molecular Cardiology Research Laboratory at Ochsner Clinic Foundation, has identified the mechanism of how a drug commonly used on stents to prevent reclosure of coronary arteries, regulates cell movement which is critical to wound healing and the progression of diseases like cancer. The study is published in the April 16th issue of the Journal of Biological Chemistry.
The antibiotic, rapamycin, is used on drug-eluting stents implanted during angioplasty because it is effective in preventing restenosis (re-narrowing or reclosure) of arteries. However, rapamycin can also prevent tissue from growing over and covering the metal stents, a critical part of the artery's healing after angioplasty. Without this protective covering, blood clots can develop many months later, called late stent thrombosis. These clots can lead to a heart attack.
"Late stent thrombosis has emerged as a major factor diminishing the benefits of drug-eluting stents, highlighting the need for a better understanding of the antimigratory mechanism of rapamycin and its analogs," notes Dr. Woods.
Through a series of experiments, the researchers found that by silencing a protein made by cells exposed to mTOR inhibitors, a class of drugs including rapamycin, they could block rapamycin's inhibitory effect on cell migration.
"We identified specific changes in proteins that a class of drugs, called mTOR inhibitors, uses to block cell movement," said Dr. Woods. "This knowledge will help us to better design strategies to help arteries heal following angioplasty or to prevent tumor growth."
Studies like this one often have application beyond the original research question because they identify basic mechanisms involved in many biologic processes. Cell migration in cancer is not only important in tumor growth, but also in the spread of cancer to other sites in the body.
Heart disease is the leading cause of death in the United States. Coronary heart disease is the most common type of heart disease. According to the American Heart Association, in 2006, an estimated 1.3 million angioplasty procedures were performed. It has been estimated that about 60% of angioplasty procedures performed now are performed with drug-eluting stents.
Cancer is the second most common cause of death in the US, accounting for nearly 1 of every 4 deaths.
The research team also included Stephanie Moss and Daniel Lightell, Jr. at Ochsner Clinic Foundation, and Steven O. Marx, MD, and Andrew R. Marks, MD from Columbia University College of Physicians and Surgeons..
This research was funded by a COBRE grant from the National Institutes of Health's National Center for Research Resources to LSU Health Sciences Center New Orleans Department of Pharmacology and grants from the Greater Southeast Affiliate of the American Heart Association to Ochsner Clinic Foundation.
LSU Health Sciences Center New Orleans educates Louisiana's health care professionals. The state's academic health leader, LSUHSC comprises a School of Medicine, the state's only School of Dentistry, Louisiana's only public School of Public Health, and Schools of Allied Health Professions, Nursing, and Graduate Studies. LSUHSC faculty take care of patients in public and private hospitals and clinics throughout the region. In the vanguard of biosciences research in a number of areas in a worldwide arena, the LSUHSC research enterprise generates jobs and enormous economic impact, LSUHSC faculty have made lifesaving discoveries and continue to work to prevent, advance treatment, or cure disease. To learn more, visit http://www.lsuhsc.edu and http://www.twitter.com/LSUHSCHealth.
AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.